Navigation Links
Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Date:3/2/2011

NEW YORK and OSAKA, Japan, March 2, 2011 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

ITI's PDE1 inhibitors are unique, orally available, preclinical stage compounds. These compounds have potential to be treatments for a variety of psychiatric and neurological diseases.

Under the terms of the agreement, ITI will receive an upfront cash payment and will be eligible to receive payments of approximately $500 million in the aggregate upon achievement of certain development milestones and up to an additional $250 million in the aggregate upon achievement of certain sales-based milestones, along with tiered royalty payments based on net sales by Takeda. Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors.

"Takeda's strength in CNS drug development and commercialization complements ITI's innovative approach to discovery, research and development," said Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc. "We are delighted to be working together with Takeda to advance the development of our novel PDE1 inhibitors. This program represents a unique approach to the treatment of cognitive impairment associated with schizophrenia (CIAS) and other disorders."

"We are able to enhance our central nervous system pipeline, one of our Core Therapeutic Areas, through this collaboration," said Shigenori Ohkawa, a member of the Board and Executive Vice President, Chief Scientific Officer of Takeda Pharmaceutical Company Limited. "We believe that ITI's PDE1 inhib
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
2. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
3. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
5. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
6. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
7. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
8. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
9. Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
10. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
11. The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  According to the American ... children spend on digital devices. An AOA survey reports ... 10 and 17 estimate they use an electronic device ... separate AOA survey of parents revealed that only 40 ... device for that same amount of time. Eye doctors ...
(Date:7/22/2014)... , July 22, 2014 Quantum Materials Corporation (OTCQB:QTMM) ... Mr. John Heaton to the Board of Directors. QMC ... Ghassan Jabbour , QMC Chief Science Officer and Board of ... Wong of Rice University and Mr. Tomio Gotoh , ... . " Quantum Materials welcomes two new ...
(Date:7/21/2014)... -- Champions Oncology (OTC: CSBR), a company engaged in the ... the development and use of oncology drugs, today announced ... the fourth quarter and fiscal year ended April 30, ... The company will host a conference call ... EDT (1:30 p.m. PDT). To participate in the call, ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... May 5, 2011 IRIDEX Corporation (Nasdaq: IRIX ) ... sales and improved financial results for the first quarter ended April ... $0.06 per diluted share, up from $0.5 million or $0.05 per ... ophthalmology sales grew 10%. Total sales increased to $11.2 million ...
... Inc. (Nasdaq: BIOD ) today reported financial results for ... Fiscal Year 2011 Financial Results Biodel reported a net ... million, or $0.21 per share, compared to a net loss of ... the prior year. Research and development expenses were ...
Cached Medicine Technology:IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 2IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 3IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 4IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 5Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 6
(Date:7/22/2014)... July 22, 2014 For more than ... cold storage consumers with dynamic, specialized humidification ... customer satisfaction. Offering 50-70% less energy requirements than ... This process is completed through a non-chemical procedure ... also provide a 4.2 Micron droplet. The size ...
(Date:7/22/2014)... Texas (PRWEB) July 22, 2014 For ... Advocate Foundation (PAF) have been working in tandem to ... insurance options, facilitate access to care, and help survivors ... 2014, the two foundations expanded their partnership to include ... by cancer deal with the other practical, emotional, and ...
(Date:7/22/2014)... Get Real Health announced today a ... (IDF) to provide their patient community with a new ... electronically track their symptoms, medications and other health-related information—enabling ... allow those patients and families who want to ... shared with the U.S. Immunodeficiency Network (USIDNET) registry, ...
(Date:7/22/2014)... Atreo Services will be presenting its full ... and accessories in booth #1423 at the American Society ... in Chicago, Ill., Aug. 3-6. , Atreo will display ... as well as its selection of liners and inserts ... In addition, representatives will be available to talk ...
(Date:7/22/2014)... Altec Products, Inc. , a leader ... their Gold Sponsorship of Sage Summit 2014 ... and Casino in Las Vegas, Nevada. The largest educational ... in taking advantage of the many opportunities to network ... and educate themselves on the latest enterprise resource planning ...
Breaking Medicine News(10 mins):Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 2Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 3Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 3Health News:Get Real Health to Partner with Immune Deficiency Foundation 2Health News:Get Real Health to Partner with Immune Deficiency Foundation 3Health News:Atreo Services to Introduce Pneumatic Tube System Solutions at ASHE Annual Conference 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 3
... -- Women may be less likely to develop premenstrual syndrome ... B vitamins, a new study suggests. Women who ... reduced their risk of PMS, the data suggested. Thiamine ... and researchers said eating two to three servings of thiamine-rich ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, March 14 ... is, a pediatrician or nurse they see regularly who offers comprehensive ... needs met, new research finds. Yet it,s the sickest children ... require the most care -- who are less likely to get ...
... for healthier humans around the globe are making headway ... diarrheal illness, according to research from the Frederick S. ... Denver,s (DU) Josef Korbel School of International Studies. ... a series of five volumes that focus on human ...
... 14, 2011The first human studies of an oral drug regimen ... near 50% reduction in HIV incidence, but a number of ... be implemented on a large scale, according to an article ... journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). ...
... Education recently received a five year, $3.7 million grant ... to fund a project aimed at preventing obesity among ... mothers simple yet authoritative strategies to promote appropriate food ... was awarded to Jenifer Orlet Fisher, associate professor of ...
... National Institute of Allergy and Infectious Diseases (NIAID), part ... the O157:H7 strain of Escherichia coli causes ... The bacterium secretes a protein called NleH1 that directs ... responses. This process not only helps the bacterium evade ...
Cached Medicine News:Health News:Diets Rich in Vitamin B May Help Prevent PMS, Study Finds 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 3Health News:DU researchers find that headway being made fighting communicable diseases globally 2Health News:DU researchers find that headway being made fighting communicable diseases globally 3Health News:Early success of anti-HIV preventive oral drug regimen is promising, but questions remain 2Health News:Temple receives $3.7 million to study parenting styles' effect on childhood obesity 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: